EYPT EyePoint Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EYPT

Price (delayed)

$12.31

Market cap

$1.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.51

Enterprise value

$974.45M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 15

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a ...

Highlights
The debt has declined by 9% year-on-year and by 2.6% since the previous quarter
EYPT's gross profit has dropped by 89% year-on-year and by 80% since the previous quarter
The revenue has dropped by 86% year-on-year and by 76% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://eyepointpharma.com
Peers: OPK ORGO

Key stats

What are the main financial stats of EYPT

EYPT stock price

How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-0.24%
1 week
-8.81%
1 month
-11.12%
1 year
50.12%
YTD
-32.62%
QTD
-4.5%

Financial performance

How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$7.62M
Gross profit
$5.83M
Operating income
-$281.82M
Net income
-$271.6M
Gross margin
76.5%
Net margin
-3,566.6%
EYPT's gross profit has dropped by 89% year-on-year and by 80% since the previous quarter
The revenue has dropped by 86% year-on-year and by 76% since the previous quarter
The net income has dropped by 85% year-on-year and by 17% since the previous quarter
The operating income has plunged by 75% YoY and by 16% from the previous quarter

Price vs fundamentals

How does EYPT's price correlate with its fundamentals

Growth

What is EyePoint Pharmaceuticals's growth rate over time

Valuation

What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.46
P/S
139.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
127.97
The EPS has contracted by 45% YoY and by 11% from the previous quarter
The stock's price to book (P/B) is 54% more than its 5-year quarterly average of 2.9 and 4% more than its last 4 quarters average of 4.3
EYPT's equity is down by 25% since the previous quarter and by 23% year-on-year
EYPT's P/S is 148% above its last 4 quarters average of 56.1
The revenue has dropped by 86% year-on-year and by 76% since the previous quarter

Efficiency

How efficient is EyePoint Pharmaceuticals business performance
EYPT's return on assets has dropped by 116% year-on-year and by 24% since the previous quarter
The ROIC has shrunk by 110% YoY and by 26% QoQ
EyePoint Pharmaceuticals's ROE has plunged by 103% YoY and by 25% from the previous quarter

Dividends

What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYPT.

Financial health

How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio is down by 28% since the previous quarter and by 22% year-on-year
EyePoint Pharmaceuticals's current ratio has decreased by 25% from the previous quarter and by 15% YoY
The debt is 91% smaller than the equity
EYPT's debt to equity is up by 29% since the previous quarter and by 29% year-on-year
EYPT's equity is down by 25% since the previous quarter and by 23% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.